MEDICALSYSTEM(SZ:300439) Quan Jing Wang·2025-11-13 13:28Group 1: Establishment of the Joint Laboratory - The signing ceremony for the establishment of the Cardiovascular Metabolism Precision Diagnosis Collaborative Innovation Joint Laboratory between Peking University First Hospital and Meikang Bio was held in Beijing [1] - The laboratory will focus on lipoprotein profiling research to identify more precise intervention targets, aiming for breakthroughs in chronic disease prevention and treatment [1][2] - The collaboration is expected to enhance personalized medical development and provide more accurate treatment plans for patients [1][3] Group 2: Importance of VAP Technology - VAP (Vertical Auto Profile) technology is highlighted as an advanced method for analyzing lipoprotein subcomponents, which is crucial for assessing cardiovascular disease risk [2][4] - The technology allows for comprehensive and precise evaluation of atherosclerotic cardiovascular disease risks and supports the efficacy evaluation of lipid-lowering medications [2][4] - VAP technology has been recognized in multiple authoritative guidelines, indicating its significance in clinical applications [5] Group 3: Meikang Bio's Role and Achievements - Meikang Bio, established in 2003, is a leading enterprise in the in vitro diagnostic industry in China, focusing on the development, production, and sales of diagnostic instruments and reagents [6] - The company has obtained numerous product registrations, including 497 for in vitro diagnostic reagents and 50 for diagnostic instruments, showcasing its extensive product line [6] - Meikang Bio aims to integrate research, production, and clinical application to enhance its competitive edge in the market [6] Group 4: Future Directions and Goals - The joint laboratory aims to build a high-level team and undertake major national projects to continuously optimize VAP technology and improve detection capabilities [3][9] - The collaboration is positioned as a significant step towards addressing residual cardiovascular risks and contributing to the "Healthy China" initiative [3][9] - Meikang Bio plans to enhance its detection and service capabilities by leveraging its advanced technology platforms to meet the growing demand for disease diagnosis and health management in China [9]